Paediatric ophthalmology five-year results of atropine 0.01% efficacy in the myopia control in a European population
Reviewed by Jonathan Chan

This a prospective, randomised and longitudinal study from Madrid, Spain in 361 eyes from 361 children randomised into the control group (177 eyes with no treatment) and the treatment group (184 eyes with 0.01% atropine drops once daily). Complete eye examination was carried out at six monthly intervals including refraction, axial length (AL), keratometry (K readings), anterior chamber depth (ACD) to examine the efficacy of the treatment. Anterior chamber depth and K readings did not show significant changes between the groups. The spherical equivalent (SE) increased by -0.63+/-0.42D in the treatment group and increased by -0.92+/- 0.56D in the control group. Axial length increased by 0.26 +/-0.28mm in the treatment group, compared with 0.49 +/-0.34mm in the control group. Atropine 0.01% showed an efficacy of 31.5% and 46.9% in the control of SE and AL respectively. The authors concluded that atropine 0.01% is safe and effective in slowing myopia progression in a European population over a five-year period. The limitations are no outdoor activities or near-distance learning time, pupil diameter or accommodation were recorded in this study.

Five-year results of atropine 0.01% efficacy in the myopia control in a European population.
Moriche-Carretera M, Revilla-Amores R, Gutiérrez-Blanco A, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2024;108(5):715–9.